SAB Biotherapeutics, Inc.
SABS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001833214
No open-market purchases or sales by SAB Biotherapeutics, Inc. insiders were filed in the last 90 days; 87 institutions reported holding it in 13F filings for Q2 2026, worth $266.8M in total; no superinvestor holds it.
Other share classesSABSW
Q3 2022 vs. Q2 2022
How the institutions holding SAB Biotherapeutics, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 37 | 40 | +3 |
| Shares | 3.08M | 3.31M | +227.0K (+7.4%) |
| Value | $4.45M | $2.32M | −$2.13M (−47.9%) |
New holders (6)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Mariner, LLC | 69,000 | $48.0K | 0.00% |
| Citadel Advisors LLC | 40,162 | $28.0K | 0.00% |
| Jane Street Group, LLC | 23,954 | $17.0K | 0.00% |
| American Portfolios Advisors | 17,466 | $12.2K | 0.00% |
| FMR LLC | 9,000 | $6.00K | 0.00% |
| China Universal Asset Management Co., Ltd. | 403 | $0 | 0.00% |
Sold out (3)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Silver Oak Securities, Inc | 51,941 | $64.0K |
| ETF Managers Group, LLC | 13,581 | $19.0K |
| Penserra Capital Management LLC | 6,405 | $9.00K |